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Trypanosoma cruzi, the etiologic agent of Chagas' disease, replicates in the
cytoplasm of mononuclear phagocytes. In vitro, factors released by antigen- or
mitogen-stimulated T lymphocytes can activate macrophages to inhibit the
growth of this protozoan (l, 2). Interferon y (IFN--y) appears to be one of the
principal lymphokines that can activate macrophages for resistance to a wide
variety of intracellular microbial pathogens (reviewed in 3), including T. cruzi (4,
5). However, there are additional macrophage-activation factors (6-10), some of
which may have a narrower spectrum of activity (7, 8). Defined cytokines with
ability to enhance macrophage antimicrobial activity include recombinant tumor
necrosis factor a (rHu-TNF-a) (tested with T. cruzi [8]) and partially purified
murine granulocyte/macrophage colony-stimulating factor (Mu-GM-CSF)'
(tested with leishmania [9]). In addition, a two- to threefold stimulation of
macrophage respiratory burst capacity was reported with partially purified mac-
rophage colony-stimulating factor (M-CSF) (10). Studies with recombinant cyto-
kines are needed to confirm macrophage activation by CSFs, characterize their
spectrum of activity, establish their potency, and explore their mechanisms of
action .
The cloning and expression (11), and purification of murine GM-CSF now
permit the study of its macrophage-activating potential using a well-characterized
population of tissue macrophages, those from the mouse peritoneal cavity. Such
studies are reported below, along with comparative experiments using rMu-IFN-
7 and experiments using human monocytes and macrophages stimulated with
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rHu-GM-CSF and Hu-IFN-y. In addition, we have compared the potency of
rMu-GM-CSF, rHu-M-CSF, rHu-TNF-a, and rMu-IFN-y for enhancement of
mouse peritoneal macrophage respiratory burst capacity, a close correlate of
their antitrypanosome (12), antitoxoplasma (13, 14), and antileishmania (14, 15)
activity.
Materials and Methods
Mice. For tests with T. cruzi, female BALB/cByj mice were purchased from The
Jackson Laboratories (Bar Harbor, ME) and used at 8-12 wk of age. For tests of H202-
releasing capacity, specific pathogen-free female BALB/c mice were purchased from
Taconic Farms (Germantown, NY) and housed under barrier conditions with autoclaved
food, water, and bedding.
Parasite.
￿
The Tulahuen isolate of T. cruzi (MHOM/CH/00/Tulahuen) was cloned by
twice-repeated microdrop selection. The clone used in these studies was designated as
MHOM/CH/00/Tulahuen C2. Trypomastigotes were produced by inoculating blood-
stream parasites from an infected mouse onto monolayers of the J774A.1 mouse macro-
phage cell line (American Type Culture Collection, Rockville, MD) grown in RPMI 1640
medium (M.A. Bioproducts, Walkersville, MD) with 10% FCS (M.A. Bioproducts) and
harvesting extracellular trypomastigotes from the cultures 5-6 d later, as described (16).
Parasites were separated from contaminating host cells by centrifugation on lymphocyte
separation medium (Litton Bionetics, Kensington, MD) and frozen at -80°C until use.




Mouse resident peritoneal cells (PC) were collected by peritoneal
lavage and were plated on 12-mm-diam glass coverslips (2.8-3 X 105 macro-
phages/coverslip) or placed in polypropylene tubes (Falcon Labware, Oxnard, CA) at 5 X
105 macrophages/tube in 0.5 ml RPMI/5% FCS. Culture media and FCS contained <0.01
ng/ml bacterial endotoxin as determined by the Limulus amoebocyte lysate assay (M.A.
Bioproducts). Cells applied to coverslips were allowed to adhere for 2 h, and then washed
vigorously to remove nonadherent cells. Infection ofPC in adherent or suspensioncultures
was carried out at a 1 :1 parasite/macrophage ratio. After 2 h of infection, suspension
cultures were centrifuged (150 g, 10 min) to remove extracellular trypanosomes, and
resuspended in fresh RPMI/10% FCS. Adherent cell cultures were rinsed thoroughly
with RPMI and cultured in RPMI/10% FCS with or without cytokine, for 5-6 d at 37°C.
At the end of the incubation period, aliquots of the suspension cultures were removed for
total cell and parasite counts. Smears were prepared by cytocentrifugation, fixed with
methanol, and stained with Giemsa for determination of intracellular parasite numbers.
Adherent cell cultures were stained with Giemsa for counting intracellular parasites.
Human peripheral blood monocytes were isolated as previously described (17). Ficoll-
Hypaque (Isolymph; Gallard-Schlesinger, Inc., Carle Place, NY) purified peripheral blood
leukocytes were fractionated by Percoll (Pharmacia Fine Chemicals, Piscataway, NJ)
continuous gradient centrifugation. The monocyte-enriched fraction was allowed to
adhere to 12-mm-diam glass coverslips (106 cells/coverslip) for 1 .5 h in RPMI/5% FCS.
Nonadherent cellswere then removed with three washes. The adherent cellswere cultured
in RPMI/5% FCS (1 ml/well) in 24-well plates (Corning Glass Works, Corning, NY) for
2 h. Macrophages were derived by incubating the cells for 7 d without added lymphokine.
Infection of monocytes or macrophages was carried out at a 1 :1 parasite/cell ratio.
Microbistatic activity was calculated as described (18) by the formulae: 100 X [(parasites
per 100 infected control cells) - (parasites per 100 infected treated cells)]/(parasites per
100 infected control cells); and 100 X [(percent infected control cells) - (percent infected
treated cells)]/(percent infected control cells).
Cytokines.
￿
Mu-GM-CSF was cloned from an LBRM-33 mC9 cDNA library and ex-
pressed in yeast. Recombinant protein was purified to homogeneity from yeast supernatant
using two cycles of reversed-phase HPLC as previously described (19). The specific activity
of purified rMuGM-CSF is 5 X 10" U/ag, as measured in the mouse bone marrow1736 MACROPHAGE ACTIVATION BY COLONY-STIMULATING FACTOR
proliferation assay (20). Hu-GM-CSF wascloned, expressed, and purified to homogeneity
as previously described (21). The specific activity of rHu-GM-CSF is 5 x 105 CFU-C/mg,
as measured in the human bone marrow colony assay (18). rMu-IFN--y (17.4 x 106 U per
1 .4 mg protein) was provided by Genentech, Inc., South San Francisco, CA, as protein
purified to homogeneity from Escherichia tali (lot 3209-33). Natural Hu-IFN-y (1 .5 x 106
U/mg) was purchased from Meloy Laboratories (Springfield, VA) and was determined to
be free of bacterial endotoxin as above. rHu-TNF-a, expressed in E. coli and purified to
homogeneity, was the gift of Genentech, Inc., and had a specific activity of 7.6 x 10'
U/mg protein in a cytotoxicity assay against actinomycin D-treated L929 cells (22). rHu-
M-CSF, expressed in Chinese hamster ovary cells and purified to homogeneity, was the
gift of Genetics Institute, Inc., Cambridge, MA, and hadaspecific activity of 2.5-5 x 105
U/mg protein in a mouse bone marrow assay (23).
11202-releasing Capacity and Measurement ofAdherent Cell Number and Protein.
￿
Using
the materials and methods previously described (24), resident mouse peritoneal cells were
plated in triplicate in 96-well plastic tissue culture trays at 2 x 105 cells/well, washed after
2 h to remove nonadherent cells, andeither assayed immediately or exposed to cytokines
for 1, 2, or 3 d. At each time, one set of washed plates (see below) was used to measure
H202 releasein response to phorbolmyristateacetate(PMA), by followingthe horseradish
peroxidase-dependent oxidation of fluorescent scopoletin to a nonfluorescent productat
intervals over 2 h in a plate-reading fluorometer. The protein content of each well was
then determined with a modification of the method of Lowry et al. (25). Both methods
have been described in detail (26). Another set ofplates was washed in the same way and
used to determine the number of adherent cells by lysing the cellsand counting the nuclei
in a hemocytometer, as described (27). Tightly adherent cells are defined as those that
remained after the plates were flicked hard enough to remove all visible fluid, immersed
by saline, and flickedagain, this procedure being repeated twicemore (26).
Statistics.
￿
Means and SEM or SD are shown for the number of experiments indicated.
p values are based on Student's t test.
Results
Inhibition ofT. cruzi in Mouse Peritoneal Macrophages by rMu-GM-CSF and rMu-
IFN-,y. The capacity of rMu-GM-CSF to induce antimicrobial activity in mouse
resident peritoneal macrophages was evaluated by adding the cytokine either
before or after infection with T. cruzi.
For the first set of experiments, glass-adherent macrophages were incubated
with 10 or 100 ng rMu-GM-CSF/ml for 24-72 h before infection with T. cruzi.
Intracellular parasite numbers were determined at 2 or 4 h after infection, and
again at 96 h after infection. As shown in Table 1, pretreatment of PC with rMu-
GM-CSF did not consistently affect parasite uptake, as determined by parasite
numbers at 2 or 4 h after infection. However, when parasite numbers were
determined 96 h later, significant (p < 0.01) inhibition of the increase in percent
macrophages infected and of the number of amastigotes per 100 infected
macrophages was noted in macrophages pretreated with rMu-GM-CSF. Inhibi-
tion was not significantly different whether preincubation proceeded for 24, 48,
or 72 h before infection, or whether 10 or 100 ng rMu-GM-CSF/ml was used.
However, the overall antitrypanosomal effect was microbistatic rather than -
cidal, in that the number of trypomastigotes per 100 macrophages increased
even in rMu-GM-CSF-treated cells.
In the second set of experiments, peritoneal macrophages were infected with
T. cruzi and washed before addition of different concentrations of rMu-GM-CSF.
5 d later, the numbers of intracellular parasites were determined (Fig. 1).TABLE I
Effects ofPreincubation ofMousePeritoneal Macrophages with rMu-GM-CSF on TheirAbility
to Inhibit IntracellularReplication ofT. cruzi
* Resident peritoneal macrophages were incubated 24 (A), 48 (B), or 72 h (C)in differentconcentra-
tionsof rMu-GM-CSF before infection with T. cruzi trypomastigotes.
$ Numbersof intracellularparasites were determined at 2 or 4 h, andat 96 h afterinfection.
SPercent inhibition of T. cruzi in macrophages preincubated with rMu-GM-CSF compared with
macrophages preincubated in medium alone.
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Inhibition of T. cruziin mouse
peritoneal macrophages by treatment with
v
￿
rMu-GM-CSF after infection in vitro. Mac-
too ° ;
￿
rophages adherent to glass coverslips were
infected with T. cruzifor2hbefore addition
75 r1
￿
of the indicated concentration of rMu-GM-
CSF. After 5 d, the coverslips were stained
7 a, ￿with Giemsa and numbers of intracellular
50 n parasites were determined. Results are
2
￿
means± SD fortriplicatecultures from each
25 0 0
￿
of two experiments. Significant (p < 0.05)
a
￿
inhibition,as compared with cultures receiv-
ing no rMu-GM-CSF, was achieved with
doses of 10-2-102 ag/ml. (0) Percent mac
rophages infected; (0) parasites per 100 in-
fected macrophages.
Treatment with rMu-GM-CSF at 10 ng/ml to 100 Ag/ml resulted in marked
microbistatic activity, expressed as reduction in the number of intracellular
parasites per 100 infected cells, and in the percentageofcells infected compared
with untreated cultures on day 5. Direct enumeration of macrophages on the
glass coverslips was determined as described (27). No net increase of mouse



















ng/ml h % %
A 0 2 5.4±4.0 9.1 - 5.9±4.8 78.8 -
0 96 14.5 t 2.1 84.7 ± 25.8
10 2 4.5 t 1.1 0.7 92 4.5 ± 1.1 22.0 72
10 96 5.2±2.4 26.5±2.1
100 2 10.2 t 3.8 -2.3 100 10.9 t 2.4 15.4 80
100 96 7.9±8.6 26.3±8.9
B 0 2 5.1±3.0 2.6 - 5.1±3.0 58.0 -
0 96 7.6±1.8 63.8±4.9
10 2 4.8±1 .5 0.4 85 9.1±2 .7 16.1 73
10 96 5.2±2.6 25.2±16.7
100 2 3.9 ±4.0 -0.9 100 3.4 t 3.0 13.0 78
100 96 3.0±2.2 16.4± 14.0
C 0 4 14.2 ±4.0 27.0 - 23.2 ± 11.0 137.8 -
0 96 41 .0±22.1 161.0±110.1
10 4 14.6±3.9 -0.6 100 21.0±7.0 41.2 70
10 96 14.0±0.0 62.2±7.11738
￿
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TABLE II
Microbistatic Activity ofMousePeritoneal Cells Stimulated with rMu-
GM-CSF
Mouse PC were cultured as adherent cells on glass coverslips or in
suspension in polypropylene culture tubes for 2 hbefore infection with T.
cruzi and subsequent addition of the indicated concentrations rMu-GM-
CSF. After incubation for 5 d, the cells were stained and intracellular
parasites counted.
not shown). Thus the observed decrease in percentage of infected cells after
cytokine treatment was not due to an increase in macrophage number.
To test the induction of microbistatic activity using mouse PC in suspension,
PC were infected in polypropylene culture tubes, washed and incubated in these
tubes for 5 d. The cells were then counted and slides prepared by cytocentrifu-
gation. In Table II, the results of suspension cultures are compared with results
obtained from adherent cell cultures. The suspension cultures inhibited parasite
replication to a similar extent as adherent cell cultures, without a net increase in
macrophage numbers.
For comparison with microbistatic activity of rMu-GM-CSF, additional cultures
of adherent mouse PC were infected with trypomastigotes, washed 2 h after
infection to remove free parasites, and incubated in different amounts of rMu-
IFN-,y. Intracellular amastigotes were counted 5-6 d later . rMu-IFN-7 was
extremely effective at inhibiting intracellular replication of T. cruzi in mouse
peritoneal macrophages, at doses as low as 0.1 ng/ml (Table III). In all experi-
ments, inhibition of the number of amastigotes per 100 cells was ?95% at 1
ng/ml. Neither rMu-GM-CSF nor rMu-IFN-7 was toxic for T. cruzi trypomasti-
gotes. After a 24 h incubation in the presence of different concentrations of
rMu-IFN-'y or rMu-GM-CSF, there was no decrease in parasite number (Table
IV) or motility (not shown) .
H202-releasing Capacity and Measurement of Adherent Cell Number and Pro-
tein. These experiments were performed with resident macrophages from
specific pathogen-free mice. As previously reported (28), in the absence of
exogenous cytokines, the number of such cells tightly adherent to the culture
surface declined by 79% over 3 d of culture. Each of the cytokines tested (rMu-
GM-CSF, rHu-M-CSF, rHu-TNF-a, and rMu-IFN--y) retarded this decline. Most
effective was rHu-M-CSF, which resulted in as many or more cells remaining
tightly adherent on day 3 as were adherent on day 0 (Fig. 2A) . In contrast, even
in the absence ofadded cytokines, the adherent cells increased in protein content
over the same period. Each of the four cytokines augmented this increase, rMu-
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Inhibition of T. cruzi in MousePeritoneal Macrophages Treatedwith rMu-IFN-,y after
Infection
Unelicited mouse peritoneal macrophages were adhered to glass coverslips, infected with T. cruzi,
washed, and incubated for5 dwith or withoutrMu-IFN-y.
TABLE IV
rMu-GM-CSF and rMu-IFN--f Are Not Toxicfor T. cruzi
Mu-GM-CSF
Mu-IFN-y
T. cruzitrypomastigotes(1 .5 X 105motile parasites in 1 ml)were incubated
(37°C) with or withoutcytokine. Numbersof motile parasites were deter-
minedafter24 h ofincubation. Results are from triplicate cultures of two
experiments.
augmented the ability of the macrophages to release H202, whether the results
were expressed per milligram of adherent cell protein (Fig. 2C) or per 106
macrophages (Fig. 2D). Peak effects were seen by 1 d with the CSFs, but not
until 2 d with rMu-IFN-,y or rHu-TNF-a. On the other hand, the magnitude of
the increase in H202-releasing capacity was far greater with rMu-IFN-,y (44-fold
greater on day 2 than for cells incubated without exogenous cytokines, mean of













1 0 11 .7±0.1 - 86.5±20.8 -
0.01 11 .6±0.5 0 89.4±13.9 0
1.0 0 100 0 100
2 0 7.4±0.7 - 64.9±32.9 -
0.01 12.8±6.0 0 62.2±37.4 4
0.1 4.2±5.5 43 14.5±17.7 78
1.0 0.3±0.4 96 0.7±0.9 99
3 0 23.1 ± 12.2 - 473.8 ± 125.6 -
0.1 2.0±0 91 10.1±1 .1 98







0 8.1 ± 2.8
1 9.6 ± 3.1
10 8.4 ± 1.2
100 8.0 ± 3.4
0.05 10.8 ± 3.2
5.0 10.5 ± 3.8
500 10.1 ± 3.51740
￿





























Comparison of rMu-GM-CSF (A),
rHu-M-CSF (V), rMu-IFN-y (O), and rHu-
TNF-a(*) with medium control (x) for ability
to augment: (A) firm adherence of macro-
phages in monolayer culture, (B) protein con-
tent per adherent macrophage, and (C and D)
H202-releasing capacity expressed (C) per mil-
ligram of adherent cell protein or (D)per 106
cells. Peritoneal macrophages from untreated,
3
￿
specific pathogen-free mice were cultured in
triplicate in 96-well plates in the indicated cy-
tokines or medium alone for 2 h (0 d) or for 1,
2, or 3 d before the plates were vigorously
washed. H202 release was determined in re-
sponse to PMA and protein was measured in
the same wells. Matched wells were used for
counting nuclei after lysing the cells. Results
aremeans t SEM for four consecutive experi-
ments (two for rHu-TNF-a) using 10 or 100
ng/ml rMu-GM-CSF, 100 ng/ml rHu-M-CSF,
1.9 ng/ml rMu-IFN-y, and 1.9 ng/ml rHu-
TNF-a.
iments) than for rMu-GM-CSF (15-fold over control, four experiments) or rM-
CSF (14-fold over control, four experiments).
The cytokines also differed markedly in the doses required (Fig. 3). rHu-M-
CSF was least potent, requiring 100 ng/ml for optimal enhancement of H202-
releasing capacity, compared with 10 ng/mlfor rMu-GM-CSF. The 50% effective
concentration (ECso) for rMu-IFN-y was 20-280 times lower than for the CSFs.
The concentrations of cytokines required for enhancement of H202 releasing
capacity were comparable to those required for induction of trypanostatic activ-
ity. Combinations of rMu-GM-CSF or rHu-M-CSF with rMu-IFN-y did not result
in synergistic increases in H202 release per milligram of cell protein. However,
such combinations did maximize the total H202-production capacity per culture,
by virtue of greater retention of adherent cells and greater increase in their size
(not shown).
In additional experiments (not shown), omission of horseradish peroxidase
eliminated the observed loss of fluorescence of scopoletin, confirming that the
measurements with CSF-treated cells reflected production of H202 rather than
nonspecific degradation of the fluorophore. In addition, rMu-GM-CSF-treated



















Dose dependence ofenhancement of H202-releasing capacity of resident mouse
peritoneal macrophages by the cytokines listed in the key. Dose-response curves were tested
on each day of culture in the same experiments described in Fig. 2. Results shownabove are
the means ± SEM for day 2 in each of those experiments. Results for the other days were
similar, except that lower doses of rMu-IFN-y were relatively more effective on day I than
day 2.
sonized trypomastigotes in place of PMA. No H202 release from the trypomas-
tigotes themselves was detected under the same conditions. Finally, when neither
trypomastigotes nor PMA was added, no H202 could be detected from untreated
macrophages or macrophages treated with any ofthe cytokines.
Effects of rHu-GM-CSF and Hu-IFN--y on the Replication of T. cruzi in Human
Monocytes and Macrophages. We next tested the inhibition of intracellular rep-
lication of T. cruzi in human peripheral blood monocytes and macrophages in
response to rHu-GM-CSF or partially purified human IFN-y. Adherent mono-
cytes were cultured for I hbefore infection with T. cruzi. The infected monolay-
ers were washed after 2 h and then recultured in the presence or absence of
lymphokine for an additional 6 d. Both rHu-GM-CSF and Hu-IFN-y inhibited
the intracellularreplication of T. cruzi, as shown in Table V. Results were similar
if the monocytes were allowed to differentiate into macrophages for 7 d before
infection (Table V).
Discussion
These results establish that rMu-GM-CSF can activate macrophages by the
dual criteria of enhanced antimicrobial activity and oxidative metabolism al-
though less effectively than rMu-IFN-y. However, rHu-GM-CSF stimulated
antimicrobial activity in human monocytes and macrophages to a degree similar
to that observed with IFN-y. rHu-M-CSF and rHu-TNF-a(24, 29)alsoenhanced
(ng/ml)
x none - -
O rIFNy ?0.05 ?1
" rTNFa ND ND
* rGM-CSF 1 10
v rM-CSF 14 1001742
￿
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TABLE V






Human peripheral blood monocytesand macrophages were prepared as described in Materialsand
Methods, infected with T. cruzi trypomastigotes, and cultured with predetermined optimal doses of
cytokine. Numbers of intracellular parasites were determined 5 d after infection. Values are from
six individual donors. Results obtained using cytokine differ (p <0.05) from those for thecontrols.
macrophage H202-secretory capacity; theirantimicrobial effects were not tested.
These findings contribute to a growing body of evidence that CSFs, originally
defined as growth factors for progenitor cells from marrow, also exert marked
effects on thein vitro survival and effector functions oftheir progenyfrom blood
(9, 10, 18, 30-33).
The contribution of CSFs to macrophage activation in vivo is unknown. GM-
CSF, which can be produced in several hours in response to bacterial lipopoly-
saccharide (34), induced a maximal increase in macrophage H202-releasing
capacity by the first time tested (^-18 h), in contrast to IFN-y, a product of
stimulated T cells, which required ^"44 h for peak effects. GM-CSF is a product
not only of T cells, but also of endothelial cells (35), fibroblasts (35, 36), and
macrophages themselves (34), all of which are widely distributed in normal
tissues. Thus, after microbial invasion, macrophage activation mediated by GM-
CSF can perhaps be attained more quickly than that obtained with IFN-'r, which
depends on recruitment and clonal expansion of antigen-specific T cells in an
infective focus. Such speculations must be tempered by the fact that the tempo
of events in vitro may not accurately reflect that in vivo, where, for example,
rMu-IFN-y fully activates mouse peritoneal macrophages within 18 h (14).
Neither rMu-GM-CSF nor rMu-IFN-y induced clear-cut trypanocidal activity
in these experiments. Rather, they induced macrophages to exert trypanostasis,
which was nearly complete in the case of rMu-IFN-y. The failure of cytokine-
treated macrophages to eradicate the parasite in vitro does not preclude their
critical participation in effective host defense in vivo. Indeed, mice treated with
rMu-IFN-y showed long-term survival from otherwise rapidly lethal T . cruzi
infection(S. Reed, manuscript submitted forpublication). Likewise, it is notclear
that the requirement for relatively high concentrations of CSFs for activation in











Medium 2,240 t 470 -
rHu-GM-CSF (10 ng/ml) 402 t 122 82
IFN--y (1,000 U/ml) 704 t 609 69
Medium 290 t 111 -
rHu-GM-CSF (10 ng/ml) 85 t 20 71
IFN-,y (1,000 U/ml) 73 t 89 75REED ET AL.
￿
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factors in vivo. Finally, the role of the respiratory burst in the inhibition of
growth of T . cruzi has not been established. However, it is possible that the
greater efficacy ofrMu-IFN-'Y-treated macrophagescompared with CSF-treated
cells can be attributed in part to their relatively greater capacity fora respiratory
burst.
Differences in cytokine preparations, the strain of T . cruzi, or assay methods
may explain the more marked effects observed here than in another study with
YMu-IFN-y (5). Previous experiments did not reveal enhanced H202-releasing
capacity after exposure of human macrophages to partially purified preparations
of natural GM-CSF or of M-CSF (37). In retrospect, the concentration of M-CSF
used in the earlier work was almost 100-fold lower than would be expected to
be effective in light of the present experiments. Likewise, there are contrasting
reports on the failure of crude natural GM-CSF (38) versus the efficacy of pure
recombinant GM-CSF (39) to activate macrophages to inhibit leishmania. These
experiences emphasize the advantage of using pure recombinant materials for
analyzing the effects of cytokines individually, and the difficulty of predicting
the outcome in situ, where cytokinesare likely to be presentin complexmixtures.
Summary
Recombinant granulocyte/macrophage colony-stimulating factors (rGM-CSF)
of mouse and human origins activated macrophages of the homologous species
to inhibit the replication of the protozoan parasite T . cruzi. Activation could be
induced with 10-100 ng/ml of rMu-GM-CSF, whether it was added before or
after uptake of theparasite, in either adherent or suspension cultures. However,
the degree of inhibition of parasite replication after exposure to rMu-GM-CSF
was not as great as after treatment with rMu-IFN-y, and much more rMu-GM-
CSF than rMu-IFN-y was required to achieve an equivalent antimicrobial effect.
These results were mirrored by effects of the cytokines on enhancement of
H202-releasing capacity in resident mouse peritoneal macrophages. In the latter
tests, rMu-IFN-y and rHu-TNF-a afforded a 44-51-fold enhancement over the
untreated control, with a 50% effective concentration (EC5o) for rMu-IFN-y of
^"0.05 ng/ml. Using rMu-GM-CSF or rM-CSF, enhancement of H202-releasing
capacity was 14-15-fold over control, with EC5osof 1 and 14 ng/ml, respectively.
However, peak enhancement of macrophage H202-releasing capacity was seen
at least 24 h earlier with rMu-GM-CSF or rHu-M-CSF than with r-Mu-IFN-y or
rHu-TNF-a. Thus, rMu-GM-CSF and rHu-GM-CSF displayed clear-cut macro-
phage-activating activity in vitro, but rMu-GM-CSF was less potent and less
effective than rMu-IFN-y in the tests used.
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